Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 976 to 990 of 1335 results for primary care

  1. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care (CG73)

    This guidance has been updated and replaced by NICE guideline CG182.

  2. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

    Evidence-based recommendations on selpercatinib (Retsevmo) for previously treated RET fusion-positive advanced non-small-cell lung cancer in adults.

  3. Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.

  4. Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)

    NICE has developed a medtech innovation briefing (MIB) on the Active-B12 assay for diagnosing vitamin B12 deficiency

  5. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

  6. Liposuction for chronic lymphoedema (IPG723)

    Evidence-based recommendations on liposuction for chronic lymphoedema in adults. This involves using suction to remove fluid and fat through punctures in the skin.

  7. Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)

    NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .

  8. Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)

    Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.

  9. Good practice guidance – Interim process statement (PMG3)

    Good practice guidance – Interim process statement

  10. Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

    Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.

  11. What are the optimal management strategies for primary hyperparathyroidism during pregnancy?

    management strategies for primary hyperparathyroidism during pregnancy? Any explanatory notes(if applicable) Care before...

  12. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

  13. Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (TA883)

    Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.

  14. Artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57)

    Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke

  15. SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)

    NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .